Manipal Health Enterprises Limited
Against an issue price of ₹590. Split- and bonus-adjusted official closes — a past move, never a forecast.
Manipal Health Enterprises Limited was a mainboard initial public offer.
The book was open from 29 July 2026 to 31 July 2026.
The issue was priced at ₹590 a share, from a band of ₹560 to ₹590.
We did not poll this issue while its book was open. The exchange publishes only the current cumulative figure and no history, so a subscription series cannot be reconstructed after an issue closes.
The shares listed on 5 August 2026.
The last official close on file is ₹747 (21 September 2026), which is 26.6% above the issue price.
It now trades as MANIPALHOS, and its filed financials are on its company page.
Shares sold in the issue at ₹590 last closed at ₹747.15.
See MANIPALHOS’s filed financials and price history →Official exchange closes, restated for splits, bonuses and rights issues since listing. A record of past price movement, not a forecast.
- Registrar
- KFin Technologies Limited
- Lead managers
- Kotak Mahindra Capital Company Limited
- Axis Capital Limited
- Goldman Sachs (India) Securities Private Limited
- Jefferies India Private Limited
- J.P. Morgan India Private Limited
- UBS Securities India Private Limited
- DBS Bank India Limited
- Bidding opens29 Jul 2026
- Bidding closes31 Jul 2026
- Basis of allotmentnot published
Not published in the exchange feeds we ingest — we do not estimate it.
- Listing5 Aug 2026
We did not poll this issue while its book was open. The exchange publishes only the current cumulative figure and no history, so a subscription series cannot be reconstructed after an issue closes.
We did not poll this issue while its book was open. The exchange publishes only the current cumulative figure and no history, so a subscription series cannot be reconstructed after an issue closes.
We have not extracted an anchor allotment list for this issue.
- Anchor investors — first trancheSEBI ICDR 2018 Reg. 32(5)(b) — 50% of the anchor allocation, 30 days from allotment4 Sept 202650% of this tranche
- Anchor investors — second trancheSEBI ICDR 2018 Reg. 32(5)(a) — the remaining 50% of the anchor allocation, 90 days from allotment3 Nov 202650% of this tranche
- All other pre-issue capitalSEBI ICDR 2018 Reg. 17 — all other pre-issue capital, 6 months from allotment5 Feb 2027whole tranche releases on this date
- Promoters' minimum contributionSEBI ICDR 2018 Reg. 16(1)(a) — promoters' minimum contribution, 18 months from allotment5 Feb 2028whole tranche releases on this date
Computed from the SEBI ICDR 2018 lock-in rules, not disclosed by the issuer or the exchange. The regulation counts from the date of allotment, which no feed we ingest publishes, so these are counted from the listing date and fall at most two to three business days later than the true expiry.
Every offer document must set out the reasoning behind its own price: what the company earned in the years before it came to market, and what multiple of those earnings it is asking for. This is that chapter — the issuer’s argument for its price, not our assessment of it.
| Year | Basic | Diluted | Weight |
|---|---|---|---|
| FY2024 | ₹5.27 | ₹5.25 | 1 |
| FY2025 | ₹9.25 | ₹9.25 | 2 |
| FY2026 | ₹7.71 | ₹7.67 | 3 |
Figures as printed in the offer document's "Basis for Offer Price" chapter. A record of the case the issuer made for its own price, not our valuation of it.
Everything we extracted from this issue's offer document is the pricing justification rather than the restated statements — it is shown under how the offer was priced. The restated financial statements themselves have not been extracted for this issue.
What the company says it will do with the money it raises. Only the fresh-issue portion reaches the company; anything raised through an offer for sale goes to the shareholders selling.
- Repa yment/ prepayment, in full or in part, of certain outstanding borrowings and accrued interest53,780₹ million
- Acqu isition of minority stake in our stepdown Subsidiary, Sahyadri Hospitals Private Limited5,740₹ million
- Gene ral corporate purposes—
Figures as filed by the issuer in its offer document.
The offer document must name the listed companies the issuer considers comparable, and print their valuation figures beside its own. This is that list — the issuer’s choice of comparison, not ours.
| Company | P/E | P/B | RoNW | EPS | Income |
|---|---|---|---|---|---|
| Apollo Hospitals Enterprise Limited | 66.2 | — | — | 135.04 | ₹2,52,285 cr |
| Fortis Healthcare Limited | 70.2 | — | — | 13.80 | ₹91,278 cr |
| Max Healthcare Institute Limited | 74.6 | — | — | 14.83 | ₹1,00,650 cr |
The issuer's own figures as printed at the head of the same table — its claim about itself, on the same basis as its claims about the companies below.
Figures as PRINTED by the issuer in its own offer document. The comparison set is the issuer's choice, not ours.
| Firm | Issues | Typical listing move | Below issue @30d | @90d | @180d |
|---|---|---|---|---|---|
Axis Capital Limited 2021 – 2026 | 85 18 measurable | +11.7% | 4 of 14 | 1 of 5 | 2 of 8 |
DBS Bank India Limited 2026 – 2026 | 1 | +13.0% | 0 of 1 | — | — |
Goldman Sachs Securities Private Limited 2024 – 2026 | 12 1 measurable | +13.0% | 0 of 1 | — | 1 of 2 |
Jefferies India Private Limited 2022 – 2026 | 25 4 measurable | +21.1% | 2 of 5 | — | — |
J. P. Morgan India Private Limited 2022 – 2026 | 23 4 measurable | +2.6% | 2 of 4 | 0 of 1 | 0 of 1 |
Kotak Mahindra Capital Company 2021 – 2026 | 64 15 measurable | +16.6% | 3 of 14 | 1 of 3 | 2 of 4 |
UBS Securities India Private Limited 2025 – 2026 | 5 2 measurable | +2.1% | 1 of 2 | — | — |
| Firm | Issues | Typical listing move | Below issue @30d | @90d | @180d |
|---|---|---|---|---|---|
Kfin Technologies Limited 2021 – 2026 | 126 30 measurable | +7.9% | 8 of 18 | 2 of 5 | 2 of 5 |
A count of what happened to the other issues each firm was named on, computed from exchange closes. Not a rating, not a ranking, and not a view on the firm.
- Prospectus· PDF · exchange archive3 Aug 2026
- Red herring prospectus (RHP)· ZIP · exchange archive23 Jul 2026
- Draft red herring prospectus (DRHP)· ZIP · exchange archive23 Mar 2026
- Abridged prospectus· PDF · exchange archive7 Apr 2026
- Anchor investor allotment· ZIP · exchange archiveThis document is a scan with no text layer — readable by eye, not by machine.
- Financial ratios advertisement· ZIP · exchange archive
Filed with SEBI and the exchanges by the issuer. These are the source for every figure on this page.
Compiled from NSE and SEBI offer documents and exchange feeds. A description of the issue and of the bids received — not investment advice, and not a view on whether to apply. No grey-market premium, no allotment lookup and no listing-gain estimate is published here.